GNH USA

Europe — EMA

Mitoxantrone Sandoz

GNH USA supplies Mitoxantrone Sandoz (Mitoxantrone), a anthracenedione antineoplastic for acute leukemia, metastatic breast cancer and prostate cancer.

Mitoxantrone

Request sourcing

1
Pack/s

What is Mitoxantrone?

Mitoxantrone, the active ingredient in Mitoxantrone Sandoz, is a anthracenedione (DNA intercalating agent, topoisomerase II inhibitor) presented as an injection solution for intravenous use. It treats acute myeloid leukemia, acute lymphoblastic leukemia, metastatic breast cancer and prostate cancer in adult patients.

GNH USA supplies Mitoxantrone Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

What is Mitoxantrone used for?

Mitoxantrone is employed in oncology regimens that target rapidly proliferating malignant cells. It is indicated for the following conditions: - Acute myeloid leukemia (AML): provides cytoreductive therapy to achieve remission. - Acute lymphoblastic leukemia (ALL): used in combination protocols to reduce leukemic burden. - Metastatic breast cancer: administered to control disease progression and improve survival. - Prostate cancer (hormone‑refractory): employed to extend survival in advanced disease.

What are the side effects of Mitoxantrone?

Adverse reactions may occur with Mitoxantrone therapy.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly reported during treatment. - Alopecia: reversible hair loss affecting scalp and body hair. - Fatigue: persistent tiredness that may limit daily activities. - Myelosuppression: reduction in blood cell counts leading to anemia, neutropenia or thrombocytopenia.

Serious or Rare Side Effects: - Cardiotoxicity: dose‑related decline in left ventricular function, potentially leading to heart failure. - Secondary acute leukemia: emergence of a new malignant clone after prolonged exposure. - Severe infections: opportunistic infections due to profound neutropenia. - Hepatic toxicity: elevated liver enzymes and rare hepatic failure. - Pulmonary fibrosis: rare scarring of lung tissue causing respiratory compromise.

What precautions apply to Mitoxantrone?

Mitoxantrone requires careful monitoring and specific safety measures. - Cardiac monitoring: obtain baseline and periodic ejection fraction assessments. - Hematologic surveillance: perform regular complete blood counts to detect myelosuppression. - Liver function evaluation: monitor transaminases and bilirubin during therapy. - Infection control: avoid initiating treatment in patients with active, uncontrolled infections. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Mitoxantrone interact with?

Mitoxantrone may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Anthracyclines (e.g., doxorubicin): additive cardiotoxicity increases risk of heart damage. - Live vaccines: immunosuppression can lead to severe vaccine‑derived infection. - Strong CYP3A4 inhibitors (e.g., ketoconazole): raise plasma concentrations and toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): enhanced anticoagulant effect may increase bleeding risk. - Granulocyte colony‑stimulating factors (e.g., filgrastim): may modify recovery from myelosuppression.

Frequently asked questions

What conditions is Mitoxantrone Sandoz used for?+
Mitoxantrone Sandoz is indicated for the treatment of acute myeloid leukemia, acute lymphoblastic leukemia, metastatic breast cancer and hormone‑refractory prostate cancer. It is administered as part of combination chemotherapy protocols to reduce tumor burden and improve survival in adult patients.
How does Mitoxantrone work in the body?+
Mitoxantrone intercalates into DNA and blocks topoisomerase II, preventing the re‑joining of DNA strands during replication. This creates double‑strand breaks, leading to apoptosis of rapidly dividing cancer cells while sparing most normal tissues.
What is the usual dose of Mitoxantrone Sandoz?+
The dose of Mitoxantrone Sandoz is individualized by the prescribing oncologist based on the specific indication, disease stage, patient weight, renal and hepatic function, and prior therapy. Only a qualified healthcare professional should determine the appropriate regimen.
Is Mitoxantrone Sandoz safe during pregnancy or breastfeeding?+
The safety of Mitoxantrone in pregnancy and lactation has not been established. It is generally contraindicated in pregnant or nursing women because of potential fetal toxicity and the risk of drug transfer through breast milk. Consultation with a specialist is essential.
How do I order Mitoxantrone Sandoz from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and necessary import documentation.
How does Mitoxantrone compare with other chemotherapy agents?+
Compared with anthracyclines such as doxorubicin, Mitoxantrone has a similar mechanism of DNA intercalation but a distinct toxicity profile, notably a higher risk of cardiotoxicity at cumulative doses. It is often chosen when a non‑anthracycline option is preferred or when resistance to other agents has developed.
What are the storage and handling requirements for Mitoxantrone Sandoz?+
Mitoxantrone Sandoz must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. The vial should remain in its original packaging until use to maintain stability.
How is Mitoxantrone Sandoz administered?+
The product is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional in a clinical setting, typically over a period of 30‑60 minutes, with appropriate monitoring of vital signs and cardiac function.
What are the most serious risks associated with Mitoxantrone therapy?+
The most serious risks include dose‑related cardiotoxicity, secondary acute leukemia, severe myelosuppression leading to infections or bleeding, and rare hepatic or pulmonary toxicity. Patients should be closely monitored for cardiac function, blood counts and organ health throughout treatment.
Who should not receive Mitoxantrone Sandoz?+
Mitoxantrone Sandoz is contraindicated in patients with known hypersensitivity to the drug or its excipients, those with uncontrolled infections, and individuals with pre‑existing severe cardiac disease. Caution is also advised for patients with significant hepatic impairment.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Mitoxantrone
Route
Intravenous Use
Manufacturer
Sandoz N.V.
Origin
EU

Related products

Mitoxan

Mitoxan

Mitoxantrone

Medicamerc S.A
EU
Mitoxantron "ebewe"

Mitoxantron "ebewe"

Mitoxantrone

Ebewe Pharma
EU
Mitoxantron Accord

Mitoxantron Accord

Mitoxantrone

Accord Healthcare B.V.
EU
Mitoxantron Ebewe

Mitoxantron Ebewe

Mitoxantrone

Ebewe Pharma
EU